SURI Simplify Propel Opportunities ETF
The Simplify Propel Opportunities ETF (SURI) seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology, and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation.
The fund is sub-advised by Propel, which uses its deep scientific and commercial expertise in health sciences to identify the most promising health science investment opportunities.
The fund is sub-advised by Propel, which uses its deep scientific and commercial expertise in health sciences to identify the most promising health science investment opportunities.
Fund Overview
As of 06/18/2026
Ticker Symbol
SURI
Gross Expense Ratio
2.82%
Net Expense Ratio
2.57%
CUSIP
82889N624
Total Assets
$72,517,511.61
Shares Outstanding
4,290,001
Distribution Rate as of 03/31/2026
Distribution rate calculation employs the most recent distribution, and multiplies the payment by 12 (monthly) or 4 (quarterly) to get an annualized total. The annualized total is then divided by the most recent net asset value (NAV) to determine the distribution rate.
Distribution Rate Close
Distribution rate calculation employs the most recent distribution, and multiplies the payment by 12 (monthly) or 4 (quarterly) to get an annualized total. The annualized total is then divided by the most recent net asset value (NAV) to determine the distribution rate.17.41%
Distribution Frequency
Quarterly
30-Day SEC Yield (Subsidized) as of 05/31/2026
0.76%
30-Day SEC Yield (Unsubsidized) as of 05/31/2026
0.51%
Options Available
No
Inception Date
02/07/2023
Premium/Discount (%) as of 06/18/2026
0.69%
NAV Per Share as of 06/18/2026
$16.90
Market Price as of 06/18/2026
$17.02
30-Day Median Bid-Ask Spread
1.03%
Bid/Ask
$16.99/$17.10
Midpoint Price
$17.05
Volume
2,406
NAV Symbol
SURI.NV
IOPV Symbol
SURI.IV
Shares Out. Symbol
SURI.SO
Schedule K-1
No
The Distribution Rate is the annual rate an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. The distribution may include a combination of ordinary dividends, capital gains, and return of investor capital and has the potential to change during any given tax year. Please refer to the 19a-1 Notice, which can be found on the Fund’s website, for information regarding the composition of distributions, including return of capital. The final determination of a distribution’s tax character will be made on Form 1099-DIV.
Management Fees
This table describes the fees and expenses that you may pay if you buy, sell, and hold shares of the Fund. Investors purchasing or selling shares of the Fund in the secondary market may be subject to costs (including customary brokerage commissions) charged by their broker. The fee table located in the prospectus and updates in prospectus supplements prevail.
| Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment) | |
|---|---|
| Management Fees1 | 2.75% |
| Distribution and Service (12b-1) Fees | 0.00% |
| Other Expenses | 0.06% |
| Acquired Fund Fees and Expenses2 | 0.01% |
| Total Annual Fund Operating Expenses | 2.82% |
| Fee Waiver3 | (0.25)% |
| Total Annual Fund Operating Expenses After Fee Waiver | 2.57% |
1. The Fund has agreed to pay the adviser as compensation under a management agreement a monthly advisory fee (as a percentage of daily net assets) computed at the annual rate of 2.75% on assets up to $1 billion; 2.50% on assets over $1 billion and less than $5 billion; 2.00% on assets over $5 billion and less than $10 billion; and 1.00% on assets over $10 billion.
2. Acquired Fund Fees and Expenses are the indirect costs of investing in other investment companies. The operating expenses in this fee table will not correlate to the expense ratio in the Fund’s financial highlights because the financial statements include only the direct operating expenses incurred by the Fund.
3. The adviser and sub-adviser have each agreed to waive its respective advisory and sub-advisory fee by 0.25% on an annualized basis through October 31, 2026.
Fund Performance (Total Return)
As of 05/31/2026 03/31/2026
| Cumulative | 1 Month | 3 Month | 6 Month | YTD | 1 Year | 3 Year | 5 Year | Since Inception |
|---|---|---|---|---|---|---|---|---|
| NAV | 2.77% | 6.20% | 5.32% | 9.14% | 42.90% | 31.05% | — | 17.26% |
| Market Price | 4.12% | 6.81% | 6.40% | 10.79% | 43.58% | 31.65% | — | 19.65% |
| Annualized | 1 Year | 3 Year | 5 Year | Since Inception |
|---|---|---|---|---|
| NAV | 42.90% | 9.43% | — | 4.93% |
| Market Price | 43.58% | 9.60% | — | 5.58% |
| Cumulative | 1 Year | 3 Year | 5 Year | Since Inception |
|---|---|---|---|---|
| NAV | 20.54% | 25.93% | — | 4.25% |
| Market Price | 19.74% | 25.49% | — | 5.12% |
| Annualized | 1 Year | 3 Year | 5 Year | Since Inception |
|---|---|---|---|---|
| NAV | 20.54% | 7.99% | — | 1.33% |
| Market Price | 19.74% | 7.86% | — | 1.60% |
| Calendar Year | NAV | Market Price |
|---|---|---|
| 2025 | 25.10% | 28.24% |
| 2024 | -10.22% | -13.17% |
| 2023 | — | — |
The performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment returns and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance data for the most recent month-end is available above.
NAV: The dollar value of a single share, based on the value of the underlying assets of the fund minus its liabilities, divided by the number of shares outstanding. Calculated at the end of each business day.
Market Price: The current price at which shares are bought and sold. Market returns are based upon the last trade price.
Growth of $10,000
The Growth of $10,000 chart reflects a hypothetical investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted. Results are not indicative of future performance.
The above frequency distribution chart presents information about the difference between the daily market price for shares of the Fund and the Fund's reported Net Asset Value. The amount that the Fund's market price is above the reported NAV is called the premium. The amount that the Fund's market price is below the reported NAV is called the discount. The market price is determined using the midpoint between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00 p.m. EST). The horizontal axis of the chart shows the premium or discount expressed in basis points. The vertical axis indicates the number of trading days in the period covered by the chart. Each bar in the chart shows the number of trading days in which the Fund traded within the premium/discount range indicated.
Portfolio Holdings
| Ticker | Name | Quantity | Weight |
|---|---|---|---|
| TELSAT | TELESAT CDA / TE 5.625 06DEC26 144A | 1,000,000 | 1.24% |
| - | 145,609 | 0.59% | |
| - | CONTRA CHINOOK THERAPE + NPV | 25,000 | 0.00% |
| ABEO | ABEONA THERAPEUTICS INC USD 0.01 | 500,342 | 3.98% |
| ACHV | ACHIEVE LIFE SCIENCES INC USD 0.001 | 1,432,105 | 9.58% |
| AQST | AQUESTIVE THERAPEUTICS IN USD 0.001 | 278,723 | 1.81% |
| ARTV | ARTIVA BIOTHERAPEUTICS I USD 0.0001 | 101,355 | 1.37% |
| CLDX | CELLDEX THERAPEUTICS INC USD 0.001 | 59,038 | 2.64% |
| CMPS | COMPASS PATHWAYS PLC USD 0.008 ADR | 114,281 | 1.97% |
| CORT | CORCEPT THERAPEUTICS INC USD 0.001 | 37,763 | 4.16% |
| DCTH | DELCATH SYS INC USD 0.01 | 261,126 | 4.21% |
| EIGRQ | EIGER BIOPHARMACEUTICALS USD 0.0001 | 90,000 | 0.00% |
| EYPT | EYEPOINT INC | 45,409 | 0.85% |
| IMUX | IMMUNIC INC USD 0.0001 | 43,893 | 0.86% |
| IVA | INVENTIVA SA NPV ADR | 313,483 | 1.54% |
| KYTX | KYVERNA THERAPEUTICS IN USD 0.00001 | 182,603 | 2.03% |
| LONA | LEONABIO INC USD 0.0001 | 149,279 | 1.68% |
| MIST | MILESTONE PHARMACEUTICALS INC NPV | 3,349,379 | 6.00% |
| OBIO | ORCHESTRA BIOMED HLDGS I USD 0.0001 | 219,387 | 1.21% |
| OCUL | OCULAR THERAPEUTIX INC USD 0.0001 | 81,051 | 1.05% |
| OVID | OVID THERAPEUTICS INC USD 0.001 | 96,817 | 0.30% |
| PAGP | PLAINS GP HLDGS L P | 1,272,360 | 40.79% |
| PALI | PALISADE BIO INC USD 0.01 | 643,633 | 1.66% |
| PHAT | PHATHOM PHARMACEUTICALS USD 0.0001 | 249,267 | 3.74% |
| SABS | SAB BIOTHERAPEUTICS INC USD 0.0001 | 149,784 | 0.83% |
| UPB | UPSTREAM BIO INC USD 0.001 | 62,113 | 0.54% |
| ZVRA | ZEVRA THERAPEUTICS INC USD 0.0001 | 96,246 | 1.71% |
| - | ACHIEVE LIFE SCIENCES I WTS 30JUN30 | 966,667 | 2.47% |
| - | EURO | 488 | 0.00% |
| - | WTS - MILESTONE PHARMACEUTICALS INC SERIES B | 1,842,974 | 0.00% |
| - | WTS - QUOIN PHARMACEUTICALS LTD - Series I | 34,895 | 0.00% |
| - | WTS - QUOIN PHARMACEUTICALS LTD - Series H | 34,895 | 0.00% |
| - | WTS - QUOIN PHARMACEUTICALS LTD - Series K | 34,895 | 0.00% |
| - | WTS - QUOIN PHARMACEUTICALS LTD - Series J | 34,895 | 0.00% |
| - | WTS - TENAYA THERAPEUTICS INC | 560,000 | 0.00% |
| - | ALTIMMUNE INC | 79,075 | 0.00% |
| - | 247,593 | 0.46% | |
| - | JASPER THERAPEUTIC WTS | 609,053 | 0.00% |
| - | Estimated Cash | 518,373 | 0.71% |
Holdings are subject to change without notice.
Recent Distributions
| Ex-Dividend Date | Record Date | Payable Date | Total Distribution |
|---|---|---|---|
| N/A | |||
| $0.68000 | |||
| $0.68000 | |||
| $0.68000 | |||
| $0.68000 |
Data in the s19 reports should not be relied upon to estimate the tax classification of distributions.
They are rough point-in-time estimates that do not line up with the fund's fiscal year end and are thus
not reflective of the tax information investors should expect. S19 reports are posted for regulatory
requirements only.
